SPOTLIGHT -
This roundtable series considers the use of CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer as discussed by participants at virtual live events.
Part 1: Abemaciclib Shows Efficacy in High-Risk Early Breast Cancer
During a live virtual event, Lowell Hart, MD, discussed the results of the monarchE trial of abemaciclib in patients with node-positive, hormone receptor–positive, HER2-negative, high-risk early breast cancer.
Part 2: Recommending Abemaciclib for Early Breast Cancer Based on Ki67 Status
During a live virtual event, Lowell Hart, MD, discussed the findings of the monarchE trial of abemaciclib in high-risk patients with early breast cancer.
Abemaciclib Shows Long-Term IDFS Benefit in HR+, HER2- Breast Cancer
Manali Bhave, MD, discusses the updated results of the MonarchE study of abemaciclib in patients with hormone receptor-positive, HER2-negative, breast cancer.
Management of HR+, HER2- Early-Stage Breast Cancer After Diagnosis
Physicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.